3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
57
Neoplasm Metastasis
3
Stage II Prostate Adenocarcinoma
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Diseases
1
Prostate Cancer With ≤10 Bone Metastases
1
Prostate Cancer Metastatic Disease
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Patient Preference
1
Neoplasms
1
Neoadjuvant Therapy
1
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
1
Metastatic Castration-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Low Risk Prostate Cancer
1
High-Risk and Oligometastatic Prostate Cancer
1
High Risk Prostate Cancer
1
Hematologic Neoplasms
1
Genital Diseases, Male
1
Castration Levels of Testosterone
1
Carcinoma, Small Cell
1
Bulbo-Spinal Atrophy, X-Linked
1
Advanced Prostate Carcinoma
1
Interventions
enzalutamide
6
Abiraterone Acetate
5
abiraterone
2
Prednisone
2
pembrolizumab
1
darolutamide
1
cabazitaxel
1
apalutamide
1
TVB-2640
1
Standard of Care
1
Radiosurgery
1
Pluvicto
1
Photons
1
Omeprazole
1
Nivolumab
1
Ipilimumab
1
Gonadotropin-Releasing Hormone
1
Exome Sequencing
1
Drug Therapy
1
CTLA-4 Antigen
1
Artificial Intelligence
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Prostatic Neoplasms, Castration-Resistant
×
apalutamide
×
Clear all
NCT03173859
2020-11-18
AERA
University of Athens
Phase 2
Withdrawn